GlassScriptPhysician profile
Jeremy Seth Pepper
NPI 1841329885
$6,624.11
in general payments reported to CMS, 2019-2025
41 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,570 · 2022: $965 · 2023: $1,386 · 2024: $1,435 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,044 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,043.77 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,051.98 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $969.34 | 2021-2025 | |
| Novo Nordisk INC | $799.16 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $757.27 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.67 | 2021-2025 | Jardiance |
| Pfizer INC. | $217.13 | 2021-2025 | |
| Glaxosmithkline, LLC. | $186.79 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Idorsia Pharmaceuticals US INC | $184.36 | 2022-2023 | Quviviq |
| Amgen INC. | $181.55 | 2021-2025 | Repatha, Otezla, Otezla |
| Eisai INC. | $166.22 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.34 | 2021-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $139.90 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $135.96 | 2023-2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $116.41 | 2021-2022 | |
| Amarin Pharma, INC. | $110.88 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Pepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.